Vipivotide Tetraxetan
Metastatic Prostate Carcinoma
Explore 229 assets in Metastatic Prostate Carcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07650240CT.gov Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial | — | Not Yet Recruiting | — | — | — |
NCT07145177CT.gov 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT07476001CT.gov Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC | — | Recruiting | — | — | — |
NCT06738303CT.gov Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06972628CT.gov Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 | — | Recruiting | — | — | — |
NCT06866938CT.gov Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer | — | Recruiting | — | — | — |
NCT06461689CT.gov Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT06531499CT.gov A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study | — | Recruiting | — | — | — |
NCT06516510CT.gov A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer | — | Terminated | — | — | — |
NCT06329830CT.gov 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer | — | Withdrawn | — | — | — |
Show 9 more trialsShow fewer
NCT06496581CT.gov Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) | — | Recruiting | — | — | — |
NCT06320067CT.gov A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06303713CT.gov LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT05766371CT.gov Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT05682443CT.gov ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC | — | Active Not Recruiting | — | — | — |
NCT05340374CT.gov Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT05113537CT.gov Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04343885CT.gov In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT03805594CT.gov 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vipivotide Tetraxetan (this asset) | Mayo Clinic | P3 | B · 62 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Carboplatin | Case Comprehensive Cancer Center | P3 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Vipivotide Tetraxetan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Adenocarcinoma | — | P3 | BB · 67 |
| Renal Cell Carcinoma | — | P3 | BB · 66 |
| Prostate Carcinoma | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vipivotide Tetraxetan in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vipivotide-tetraxetan-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →